AHA: Supervised Exercise Ups 6-Minute Walking Distance in PAD

Share this content:
AHA: Supervised Exercise Ups 6-Minute Walking Distance in PAD
AHA: Supervised Exercise Ups 6-Minute Walking Distance in PAD

THURSDAY, Nov. 16, 2017 (HealthDay News) -- Supervised treadmill exercise, but not granulocyte-macrophage colony-stimulating factor (GM-CSF), improves six-minute walking distance among patients with peripheral artery disease (PAD), according to a study published online Nov. 15 in the Journal of the American Medical Association to coincide with the American Heart Association's Scientific Sessions, held Nov. 11 to 15 in Anaheim, California.

Mary M. McDermott, M.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues randomized patients with PAD to receive supervised exercise + GM-CSF (exercise + GM-CSF; 53 participants), supervised exercise + placebo (exercise alone; 53 participants), attention control + GM-CSF (GM-CSF alone; 53 participants), and attention control + placebo (51 participants).

The researchers found that there was no significant improvement in the six-minute walk distance for exercise + GM-CSF versus exercise alone (mean difference, −6.3 m [95 percent confidence interval, −30.2 to +17.6]; P = 0.61) or versus GM-CSF alone (mean difference, +28.7 m [95 percent confidence interval, +5.1 to +52.3]; Hochberg-adjusted P = 0.052) at 12-week follow-up. Compared with attention control + placebo, GM-CSF alone did not improve six-minute walk (mean difference, −1.4 m [95 percent confidence interval, −25.2 to +22.4]; P = 0.91), while exercise alone did improve six-minute walk significantly (mean difference, + 33.6 m [95 percent confidence interval, +9,4 to + 57.7]; Hochberg-adjusted P = 0.02).

"These results confirm the benefits of exercise but do not support using GM-CSF to treat walking impairment in patients with PAD," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »